Artificial intelligence is moving from pilot programs to operational infrastructure across US healthcare, and that shift is forcing regulators to confront how software influences diagnosis, treatment, reimbursement, and patient safety. AI is no longer a digital health side category. It now sits inside clinical workflows, revenue cycle systems, imaging pipelines, and medical decision support platforms. … Read more
The decision-making processes of FDA advisory committees play a pivotal role in shaping the regulatory trajectory of drugs, biologics, and medical devices in the United States. These committees, composed of independent experts in clinical medicine, biostatistics, and related disciplines, provide nonbinding recommendations that inform the U.S. Food and Drug Administration’s final determinations. While the FDA … Read more
Export compliance for healthcare products has become a critical operational and strategic priority for life sciences companies operating in global markets. As supply chains expand and regulatory scrutiny intensifies, manufacturers of pharmaceuticals, biologics, medical devices, and diagnostics must navigate a complex web of US export controls, trade sanctions, and product-specific regulations. Failure to comply can … Read more
Patent activity in life sciences has become a critical signal of innovation velocity, capital allocation, and long-term competitive positioning. Recent filing trends across the biotechnology and pharmaceutical sectors indicate a shift toward platform technologies, biologics, and data-driven therapeutics, reflecting both scientific advancement and evolving regulatory expectations in the United States. Filings are increasingly structured to … Read more
Research ethics committees play a central role in safeguarding participant welfare and maintaining scientific integrity across US clinical and biomedical research. Commonly referred to as Institutional Review Boards, these committees evaluate study protocols to ensure compliance with federal regulations, ethical standards, and risk minimization principles. As clinical innovation accelerates, particularly in biotechnology and precision medicine, … Read more
Good Manufacturing Practice, GMP, remains a foundational requirement for biotech manufacturing in the United States, governing how biologics, cell therapies, and advanced therapeutics are produced at scale. As pipelines shift toward complex modalities, regulatory expectations from the U.S. Food and Drug Administration are becoming more stringent, particularly in areas such as process control, data integrity, … Read more
Transparency in clinical data reporting has become a central pillar of regulatory compliance and market credibility within the U.S. biotechnology sector. As clinical trials grow more complex and globally distributed, stakeholders, including regulators, investors, and patients, are demanding greater visibility into trial design, outcomes, and data integrity. This shift is not only ethical but also … Read more
Antiviral material testing standards in the United States have gained increased regulatory and commercial attention as healthcare systems, manufacturers, and public health agencies prioritize infection control across clinical and consumer environments. These standards define how materials are evaluated for their ability to inactivate or reduce viral load on surfaces, textiles, and medical devices, with implications … Read more
Regulatory review timelines for medical devices in 2026 remain a critical determinant of commercialization strategy in the United States. Device manufacturers must navigate a structured but evolving framework governed by the Food and Drug Administration, where review speed is influenced by device classification, submission pathway, and data quality. As innovation accelerates across digital health, diagnostics, … Read more
Federal oversight of gene therapy research occupies a central role in shaping how advanced genetic medicines are developed, tested, and translated into clinical practice in the United States. As gene therapies move from experimental science toward commercial reality, regulatory scrutiny has intensified to ensure patient safety, scientific rigor, and long-term accountability. Unlike traditional pharmaceuticals, gene … Read more